Press Releases

Date Title    
Toggle Summary Editas Medicine Announces Second Quarter 2019 Results and Update
Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in Brilliance trial on track for 2H19 EDIT-301 for hemoglobinopathies pre-clinical in vivo data to be presented by YE19 Cash, cash
Toggle Summary Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer
CAMBRIDGE, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed Cynthia (Cindy) Collins , a 30-plus year industry veteran currently serving as the Company’s interim CEO
Toggle Summary Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, August 6, 2019 , at 5:00 p.m. ET to discuss a corporate update and results for the second quarter
Toggle Summary Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
Expect first patient dosing in second half of 2019 DUBLIN, Ireland and CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the Brilliance
Toggle Summary Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass. , June 15, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today
Toggle Summary Editas Medicine Announces First Quarter 2019 Results and Update
- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587) for LCA10 on track for first patient dosing in second half of 2019 - - Initiated IND-enabling activities for potentially
Toggle Summary Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, May 7, 2019 , at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of
Toggle Summary Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)
DUBLIN, Ireland and CAMBRIDGE, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced initial data from the ongoing natural history study to evaluate patients
Toggle Summary Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers – CAMBRIDGE,
Toggle Summary Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
EDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019 Advancing potentially best-in-class engineered cell medicine for sickle cell disease and beta-thalassemia Appointed Cynthia Collins and David Scadden , M.D., to Board
Toggle Summary Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®
CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates around the world to help elevate
Toggle Summary Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results
CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 28, 2019 , at 5:00 p.m. ET to discuss a corporate update and results for the fourth
Toggle Summary Editas Medicine Names David Scadden, M.D., to Board of Directors
CAMBRIDGE, Mass. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden , M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the
Toggle Summary Editas Medicine Announces Chief Executive Officer Transition
Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced
Toggle Summary Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
CAMBRIDGE, Mass. , Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR
Toggle Summary Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference ,  Editas Medicine, Inc.  (Nasdaq: EDIT) President and CEO Katrine Bosley will discuss the Company’s plans to
Toggle Summary Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9,
Toggle Summary Editas Medicine Announces Transition of Chief Financial Officer
CAMBRIDGE, Mass. , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack , M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019 , to return to the investment
Toggle Summary Editas Medicine Names Cynthia Collins to Board of Directors
CAMBRIDGE, Mass. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life
Toggle Summary Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
Data support opportunities to develop best-in-class, durable medicines for hemoglobinopathies CAMBRIDGE, Mass. , Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome
Toggle Summary Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass. , Nov. 30, 2018 (GLOBE NEWSWIRE) --   Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today
Toggle Summary Editas Medicine Announces Third Quarter 2018 Results and Update
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight novel Sickle Cell Disease and Beta-Thalassemia program Strong balance sheet with $337 million of cash,
Toggle Summary Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the third
Toggle Summary Editas Medicine Grows Scientific Leadership with Two New Appointments
CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan , Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President of Immunogenetics. Dr.
Toggle Summary Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
CAMBRIDGE, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S.
Toggle Summary Editas Medicine Announces Transition of Chief Medical Officer
CAMBRIDGE, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox , M.D., Ph.D., will be stepping down from the Company at the end of the year.
Toggle Summary Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
CAMBRIDGE, Mass. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101.
Toggle Summary Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
  Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that
Toggle Summary Editas Medicine Announces Second Quarter 2018 Results and Update
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101 Investigational New Drug (IND) application in October 2018 Strong balance sheet to advance Company
Toggle Summary Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of
Toggle Summary Editas Medicine to Participate in The JMP Securities Life Sciences Conference
CAMBRIDGE, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20 , 2018. 
Toggle Summary Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
Presentation at the Annual Meeting of the American Society of Gene & Cell Therapy CAMBRIDGE, Mass. , May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 was
Toggle Summary Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 , at 8 a.m.
Toggle Summary Editas Medicine Announces First Quarter 2018 Results and Update
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield , Ph.D. Cash, cash equivalents, and marketable securities of $359 million as of March 31, 2018 CAMBRIDGE, Mass.
Toggle Summary Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of tolerability and immunogenicity data from a study of EDIT-101 following subretinal injection in non-human primates CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific
Toggle Summary Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of
Toggle Summary Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
CAMBRIDGE, Mass. , March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately. Mr. Mullen has more than 30 years of experience building
Toggle Summary Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals Year-end cash, cash equivalents, and marketable securities of $329 million expected to
Toggle Summary Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
CAMBRIDGE, Mass. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day ® today.
Toggle Summary Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
CAMBRIDGE, Mass. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter
Toggle Summary Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
CAMBRIDGE, Mass. , Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield , Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Committee of the
Toggle Summary Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows: BIO CEO & Investor Conference Date:   Monday, February 12, 2018 Forum:  
Toggle Summary Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further
Toggle Summary Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36 th Annual J.P. Morgan Healthcare Conference on Wednesday, January
Toggle Summary Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
Experiments support opportunities to develop best-in-class therapies for hemoglobinopathies CAMBRIDGE, Mass. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome
Toggle Summary Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are expected to be
Toggle Summary Editas Medicine, Inc., Announces Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in an underwritten public offering.
Toggle Summary Editas Medicine Announces Third Quarter 2017 Results and Update
CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2017 , and provided an update on recent achievements and upcoming events.
Toggle Summary Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 , at 5:00 p.m. ET to discuss a corporate update and results for the third quarter
Toggle Summary Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice
Productive gene editing rates with EDIT-101 were stable over six months in transgenic mice CAMBRIDGE, Mass. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study in transgenic mice demonstrating
Toggle Summary Editas Medicine to Participate in Investor Conferences in October
CAMBRIDGE, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October.  Details are as follows: Chardan Gene Therapy Conference Tuesday,
Toggle Summary Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
Toggle Summary Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
Toggle Summary Editas Medicine Announces Second Quarter 2017 Results and Update
Toggle Summary Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment